Ewa Ehrenborg

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8135308/publications.pdf

Version: 2024-02-01

34 papers	1,785 citations	361413 20 h-index	395702 33 g-index
34 all docs	34 docs citations	34 times ranked	2766 citing authors

#	Article	IF	Citations
1	Plaque Evaluation by Ultrasound and Transcriptomics Reveals BCLAF1 as a Regulator of Smooth Muscle Cell Lipid Transdifferentiation in Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 659-676.	2.4	12
2	Subclinical atherosclerosis and its progression are modulated by PLIN2 through a feedâ€forward loop between LXR and autophagy. Journal of Internal Medicine, 2019, 286, 660-675.	6.0	18
3	Cardiac expression of the microsomal triglyceride transport protein protects the heart function during ischemia. Journal of Molecular and Cellular Cardiology, 2019, 137, 1-8.	1.9	3
4	Upregulated Autophagy in Calcific Aortic Valve Stenosis Confers Protection of Valvular Interstitial Cells. International Journal of Molecular Sciences, 2019, 20, 1486.	4.1	16
5	Local Delivery of miR-21 Stabilizes Fibrous Caps in Vulnerable Atherosclerotic Lesions. Molecular Therapy, 2018, 26, 1040-1055.	8.2	75
6	Lack of genetic susceptibility in takotsubo cardiomyopathy: a case-control study. BMC Medical Genetics, 2018, 19, 39.	2.1	14
7	Deficiency in perilipin 5 reduces mitochondrial function and membrane depolarization in mouse hearts. International Journal of Biochemistry and Cell Biology, 2017, 91, 9-13.	2.8	17
8	A Case-Control Study of Risk Markers andÂMortality in Takotsubo Stress Cardiomyopathy. Journal of the American College of Cardiology, 2016, 67, 1931-1936.	2.8	146
9	MicroRNA 486-3P as a stability marker in acute coronary syndrome. Bioscience Reports, 2016, 36, .	2.4	27
10	Phenotypic Modulation of Smooth Muscle Cells in Atherosclerosis Is Associated With Downregulation of LMOD1, SYNPO2, PDLIM7, PLN , and SYNM. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1947-1961.	2.4	64
11	Perilipin 5 is protective in the ischemic heart. International Journal of Cardiology, 2016, 219, 446-454.	1.7	43
12	ATG16L1 Expression in Carotid Atherosclerotic Plaques Is Associated With Plaque Vulnerability. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1226-1235.	2.4	37
13	Peroxisome proliferator-activated receptor delta and cardiovascular disease. Atherosclerosis, 2013, 231, 95-106.	0.8	29
14	The minor allele of the missense polymorphism Ser251Pro in perilipin 2 (PLIN2) disrupts an Î±â€helix, affects lipolysis, and is associated with reduced plasma triglyceride concentration in humans. FASEB Journal, 2013, 27, 3090-3099.	0.5	44
15	MicroRNA-9 regulates the expression of peroxisome proliferator-activated receptor Î´ in human monocytes during the inflammatory response. International Journal of Molecular Medicine, 2013, 31, 1003-1010.	4.0	74
16	Inactivation of lipoprotein lipase occurs on the surface of THP-1 macrophages where oligomers of angiopoietin-like protein 4 are formed. Biochemical and Biophysical Research Communications, 2012, 425, 138-143.	2.1	32
17	Novel mutations in microsomal triglyceride transfer protein including maternal uniparental disomy in two patients with abetalipoproteinemia. Clinical Genetics, 2012, 82, 197-200.	2.0	12
18	Allele-specific regulation of MTTP expression influences the risk of ischemic heart disease. Journal of Lipid Research, 2010, 51, 103-111.	4.2	18

#	Article	IF	Citations
19	Stereotyping at the undergraduate level revealed during interprofessional learning between future doctors and biomedical scientists. Journal of Interprofessional Care, 2010, 24, 53-62.	1.7	19
20	Regulation of Skeletal Muscle Physiology and Metabolism by Peroxisome Proliferator-Activated Receptor Î´. Pharmacological Reviews, 2009, 61, 373-393.	16.0	197
21	PPARdelta increases expression of the human apolipoprotein A-II gene in human liver cells. International Journal of Molecular Medicine, 2008, 21, 819-24.	4.0	11
22	Open-ended assignments and student responsibility. Biochemistry and Molecular Biology Education, 2007, 35, 187-192.	1.2	13
23	The Ile128Thr polymorphism influences stability and ligand binding properties of the microsomal triglyceride transfer protein. Journal of Lipid Research, 2006, 47, 1378-1385.	4.2	21
24	Activation of Peroxisome Proliferator-Activated Receptor Î´ Stimulates the Proliferation of Human Breast and Prostate Cancer Cell Lines. Cancer Research, 2004, 64, 3162-3170.	0.9	163
25	The Microsomal Triglyceride Transfer Protein Gene-493T Variant Lowers Cholesterol But Increases the Risk of Coronary Heart Disease. Circulation, 2004, 109, 2279-2284.	1.6	68
26	Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men. Journal of Internal Medicine, 2003, 254, 597-604.	6.0	82
27	Evidence That Peroxisome Proliferatorâ€“Activated Receptor Delta Influences Cholesterol Metabolism in Men. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 637-643.	2.4	125
28	Variants of the microsomal triglyceride transfer protein gene are associated with plasma cholesterol levels and body mass index. Journal of Lipid Research, 2002, 43, 51-58.	4.2	75
29	Variants of the microsomal triglyceride transfer protein gene are associated with plasma cholesterol levels and body mass index. Journal of Lipid Research, 2002, 43, 51-8.	4.2	59
30	The Q/E27 polymorphism in the Î²₂â€adrenoceptor gene is associated with increased body weight and dyslipoproteinaemia involving triglycerideâ€rich lipoproteins. Journal of Internal Medicine, 2000, 247, 651-656.	6.0	68
31	Characterization of the human peroxisome proliferator activated receptor delta gene and its expression.. International Journal of Molecular Medicine, 2000, 6, 73-81.	4.0	57
32	Characterization and chromosomal localization of the human insulin-like growth factor-binding protein 6 gene. Mammalian Genome, 1999, 10, 376-380.	2.2	11
33	A Common Functional Polymorphism in the Promoter Region of the Microsomal Triglyceride Transfer Protein Gene Influences Plasma LDL Levels. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 756-761.	2.4	130
34	The tyrosine kinase inhibitor nilotinib targets discoidin domain receptor 2 in calcific aortic valve stenosis.. British Journal of Pharmacology, 0, , .	5.4	5